Carboplatin in the treatment of ovarian cancer

David S Alberts, Nancy Mason-Liddil

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Carboplatin, a new cisplatin analogue, appears as active as cisplatin in patients with advanced ovarian cancer, but in phase I and II trials has proven significantly less toxic. In single-agent phase II trials, carboplatin has been associated with clinical complete response (CR) rates of up to 13% and overall objective response rates of up to 32% in patients with prior cisplatin exposure. As first-line treatment in phase II trials, single-agent carboplatin has produced clinical CR rates ranging from 9% to 62% and overall objective response rates of 45% to 85%. In phase III trials in this patient population, single-agent carboplatin has been associated with clinical CR rates comparable with or exceeding those of single-agent cisplatin. Phase I/II trials of combination chemotherapy have yielded overall objective response rates of 44% to 75% when carboplatin was combined with either cyclophosphamide or chlorambucil. In randomized phase III trials of combination chemotherapy, response rates similar to those of cisplatin have been achieved. However, toxicities were greatly reduced in the carboplatin-treated patients. The data from these phase I, II, and III trials document that carboplatin is as active as cisplatin in patients with advanced ovarian cancer and is associated with a significantly lower incidence of emesis, ototoxicity, peripheral neuropathy, and renal dysfunction. Thus, carboplatin may become the platinum compound of choice in the first-line treatment of advanced ovarian cancer.

Original languageEnglish (US)
Pages (from-to)19-26
Number of pages8
JournalSeminars in Oncology
Volume16
Issue number2 SUPPL. 5
StatePublished - 1989

Fingerprint

Carboplatin
Ovarian Neoplasms
Cisplatin
Therapeutics
Combination Drug Therapy
Platinum Compounds
Chlorambucil
Poisons
Peripheral Nervous System Diseases
Cyclophosphamide
Vomiting
Kidney
Incidence
Population

ASJC Scopus subject areas

  • Oncology

Cite this

Alberts, D. S., & Mason-Liddil, N. (1989). Carboplatin in the treatment of ovarian cancer. Seminars in Oncology, 16(2 SUPPL. 5), 19-26.

Carboplatin in the treatment of ovarian cancer. / Alberts, David S; Mason-Liddil, Nancy.

In: Seminars in Oncology, Vol. 16, No. 2 SUPPL. 5, 1989, p. 19-26.

Research output: Contribution to journalArticle

Alberts, DS & Mason-Liddil, N 1989, 'Carboplatin in the treatment of ovarian cancer', Seminars in Oncology, vol. 16, no. 2 SUPPL. 5, pp. 19-26.
Alberts, David S ; Mason-Liddil, Nancy. / Carboplatin in the treatment of ovarian cancer. In: Seminars in Oncology. 1989 ; Vol. 16, No. 2 SUPPL. 5. pp. 19-26.
@article{b6dcda3aa0904535a02bd4f55fd877d2,
title = "Carboplatin in the treatment of ovarian cancer",
abstract = "Carboplatin, a new cisplatin analogue, appears as active as cisplatin in patients with advanced ovarian cancer, but in phase I and II trials has proven significantly less toxic. In single-agent phase II trials, carboplatin has been associated with clinical complete response (CR) rates of up to 13{\%} and overall objective response rates of up to 32{\%} in patients with prior cisplatin exposure. As first-line treatment in phase II trials, single-agent carboplatin has produced clinical CR rates ranging from 9{\%} to 62{\%} and overall objective response rates of 45{\%} to 85{\%}. In phase III trials in this patient population, single-agent carboplatin has been associated with clinical CR rates comparable with or exceeding those of single-agent cisplatin. Phase I/II trials of combination chemotherapy have yielded overall objective response rates of 44{\%} to 75{\%} when carboplatin was combined with either cyclophosphamide or chlorambucil. In randomized phase III trials of combination chemotherapy, response rates similar to those of cisplatin have been achieved. However, toxicities were greatly reduced in the carboplatin-treated patients. The data from these phase I, II, and III trials document that carboplatin is as active as cisplatin in patients with advanced ovarian cancer and is associated with a significantly lower incidence of emesis, ototoxicity, peripheral neuropathy, and renal dysfunction. Thus, carboplatin may become the platinum compound of choice in the first-line treatment of advanced ovarian cancer.",
author = "Alberts, {David S} and Nancy Mason-Liddil",
year = "1989",
language = "English (US)",
volume = "16",
pages = "19--26",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 5",

}

TY - JOUR

T1 - Carboplatin in the treatment of ovarian cancer

AU - Alberts, David S

AU - Mason-Liddil, Nancy

PY - 1989

Y1 - 1989

N2 - Carboplatin, a new cisplatin analogue, appears as active as cisplatin in patients with advanced ovarian cancer, but in phase I and II trials has proven significantly less toxic. In single-agent phase II trials, carboplatin has been associated with clinical complete response (CR) rates of up to 13% and overall objective response rates of up to 32% in patients with prior cisplatin exposure. As first-line treatment in phase II trials, single-agent carboplatin has produced clinical CR rates ranging from 9% to 62% and overall objective response rates of 45% to 85%. In phase III trials in this patient population, single-agent carboplatin has been associated with clinical CR rates comparable with or exceeding those of single-agent cisplatin. Phase I/II trials of combination chemotherapy have yielded overall objective response rates of 44% to 75% when carboplatin was combined with either cyclophosphamide or chlorambucil. In randomized phase III trials of combination chemotherapy, response rates similar to those of cisplatin have been achieved. However, toxicities were greatly reduced in the carboplatin-treated patients. The data from these phase I, II, and III trials document that carboplatin is as active as cisplatin in patients with advanced ovarian cancer and is associated with a significantly lower incidence of emesis, ototoxicity, peripheral neuropathy, and renal dysfunction. Thus, carboplatin may become the platinum compound of choice in the first-line treatment of advanced ovarian cancer.

AB - Carboplatin, a new cisplatin analogue, appears as active as cisplatin in patients with advanced ovarian cancer, but in phase I and II trials has proven significantly less toxic. In single-agent phase II trials, carboplatin has been associated with clinical complete response (CR) rates of up to 13% and overall objective response rates of up to 32% in patients with prior cisplatin exposure. As first-line treatment in phase II trials, single-agent carboplatin has produced clinical CR rates ranging from 9% to 62% and overall objective response rates of 45% to 85%. In phase III trials in this patient population, single-agent carboplatin has been associated with clinical CR rates comparable with or exceeding those of single-agent cisplatin. Phase I/II trials of combination chemotherapy have yielded overall objective response rates of 44% to 75% when carboplatin was combined with either cyclophosphamide or chlorambucil. In randomized phase III trials of combination chemotherapy, response rates similar to those of cisplatin have been achieved. However, toxicities were greatly reduced in the carboplatin-treated patients. The data from these phase I, II, and III trials document that carboplatin is as active as cisplatin in patients with advanced ovarian cancer and is associated with a significantly lower incidence of emesis, ototoxicity, peripheral neuropathy, and renal dysfunction. Thus, carboplatin may become the platinum compound of choice in the first-line treatment of advanced ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0024371752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024371752&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 19

EP - 26

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 5

ER -